Detail page

Knowledge Web

Person

Martin Christian Müller (1972-)

Arzt

Name	Martin Christian Müller
Time	1972- (Date of birth and death)
Place	Deutschland
Academic degree	apl. Prof. Dr. med.
Profession	Arzt (characteristic profession)
Variant	Martin C. Müller M. Muller M. C. Müller Martin C. Mueller Martin Müller
Further information	Diss. Fakultät für Klinische Medizin; Dozent an der III. Medizinischen Klinik der Medizinischen Fakultät Mannheim der Universität Heidelberg; Habil.-Schrift an der Medizinischen Fakultät Mannheim der Universität Heidelberg
Record type	Person
GND-Identifier	121360296
Record ID	121360296
Involved in show all Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV Protektive Effekte des ER Chaperons GRP78 in der Doxorubizinkardiotoxizität Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia Chronische myeloische Leukämie : ELN-Update 2013 ; Empfehlungen zum Therapiemanagement Die Bedeutung von antilymphozytären Antikörpern in der Immunpathogenese der HIV-Erkrankung bei Erwachsenen sowie bei Kindern HIV-positiver Mütter

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Martin Christian Müller (1972-)

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

Protektive Effekte des ER Chaperons GRP78 in der Doxorubizinkardiotoxizität

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

Chronische myeloische Leukämie : ELN-Update 2013 ; Empfehlungen zum Therapiemanagement

Die Bedeutung von antilymphozytären Antikörpern in der Immunpathogenese der HIV-Erkrankung bei Erwachsenen sowie bei Kindern HIV-positiver Mütter